Drug intelligence / Profile preview

11C-ER176 + 18F-SMBT1

Development stage
Unknown
Lead developer
Methodist Hospital Research Institute
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

11C-ER176 + 18F-SMBT1 is an investigational combination of two positron emission tomography (PET) radiopharmaceuticals developed by The Methodist Hospital Research Institute for neuroimaging research. 11C-ER176 is a carbon-11-labeled small molecule that targets the 18-kDa Translocator Protein (TSPO), a biomarker for neuroinflammation expressed in both microglia and astrocytes. It is a second-generation TSPO tracer designed to be insensitive to the rs6971 single nucleotide polymorphism, which typically affects tracer binding affinity in humans. 18F-SMBT1 is a fluorine-18-labeled tracer that selectively targets Monoamine Oxidase B (MAO-B), an enzyme upregulated in reactive astrocytes. By combining these two tracers, researchers can use mathematical modeling to differentiate the specific inflammatory contributions of microglia and astrocytes in the living human brain, particularly in the context of Alzheimer's disease and other neurodegenerative conditions.

Other names
11C-(R)-N-sec-butyl-4-(2-chlorophenyl)-N-methylquinazoline-2-carboxamide11C-ER-17618F-SMBT-1
02

Targets

Beyond the preview

Go deeper on 11C-ER176 + 18F-SMBT1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 11C-ER176 + 18F-SMBT1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call